<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842501</url>
  </required_header>
  <id_info>
    <org_study_id>GOLO1703</org_study_id>
    <nct_id>NCT03842501</nct_id>
  </id_info>
  <brief_title>Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Golo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind placebo-controlled study was intended to measure the effects of
      the GWMP with Release supplement versus GWMP with placebo supplement in a representative
      group of obese subjects with or without diabetes at one outpatient medical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">December 24, 2018</completion_date>
  <primary_completion_date type="Actual">December 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1C from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Release supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Release Supplement</intervention_name>
    <description>Calorie reduced diet plus Release supplement</description>
    <arm_group_label>Release supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calorie reduced diet plus Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years and ≤ 80 years

          2. Body mass index (BMI) ≥ 30 and ≤ 60 kg/m2

          3. Have the ability to engage in at least 15 minutes of moderate physical activity such
             as brisk walking

          4. Willing to comply with study procedures described herein

        Exclusion Criteria:

          1. Current diagnosis of type 1 diabetes

          2. Subjects with a history of hypoglycemia

          3. A history of an eating disorder as defined by the Diagnostic and Statistical Manual of
             Mental Disorders, Fifth Edition (DSM-5)

          4. Known allergy to any of the components in the Release supplement

          5. A history of prior surgery for weight loss

          6. Currently taking injectable medications to control diabetes, including insulin and
             GLP-1 agonists

          7. Currently pregnant or breastfeeding or have had a baby within the last six weeks

          8. Planning to become pregnant in the next three months. Women of child bearing potential
             must be willing and able to use adequate and reliable contraception throughout the
             study (e.g. abstinence or barrier with additional spermicidal foam or jelly, or the
             use of intrauterine device or hormonal contraception).

          9. Uncontrolled hypertension at screening defined as Systolic blood pressure greater than
             180 mmHG or Diastolic blood pressure greater than 110 mmHG

         10. Current clinical diagnosis or signs and symptoms of unstable (in the opinion of the
             principle investigator) heart, kidney or liver disease, cancer, or chronic
             neurological disease.

         11. Current participation in any other weight loss or weight management program

         12. Currently taking weight loss medications, or medications or supplements known to be
             associated with significant weight loss or weight gain

         13. Has any condition that, in the opinion of the investigator, would make participation
             in this study not in the best interest of the subject or that could prevent, limit or
             confound the protocol-specified assessments. Examples include: history of diabetic
             ketoacidosis; active chronic liver disease or cirrhosis; chronic autoimmune disease;
             inflammatory bowel disease, colonic ulceration, partial intestinal obstruction,
             subjects predisposed to intestinal obstruction; chronic intestinal diseases associated
             with marked disorders of digestion or absorption

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Buynak Clinical Research</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

